KRAS G12C inhibitors in KRASG12C-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis - Top-Institutions - MDSpire

KRAS G12C inhibitors in KRASG12C-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis

  • By

  • Yici Yan

  • Leyi Zheng

  • Hongfei Wang

  • Leitao Sun

  • Xing Xu

  • July 10, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Oncology

  • #2

    University of California, Los Angeles (UCLA) Health
    University of California, Los Angeles (UCLA) Health

    Los Angeles, California

    Key Differentiators

    • Oncology

  • #3

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #4

    Moffitt Cancer Center
    Moffitt Cancer Center

    Tampa, Florida

    Key Differentiators

    • Oncology

Original Source(s)

KRAS G12C inhibitors in KRASG12C-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis

  • by Yici Yan, Leyi Zheng, Hongfei Wang, Leitao Sun, Xing Xu

  • July 10, 2026

Related Content

NLRP12 in cancer: a context-dependent regulator of tumor progression, immunity, and metabolism

Berberine restrains the expansion of colorectal cancer organoids by blocking cell cycle progression and reducing lipid synthesis

A phase II clinical trial of neoadjuvant chemotherapy combined with immunotherapy and different radiotherapy fractionation regimens in HR+/HER2- breast cancer